

 B.S. Aquino Drive, Bacolod City, Negros Occidental, 6100 DR. PABLO O. TORRE MEMORIAL HOSPITAL	Document Code:	DPOTMH-E-55-P01-S18
	Effective Date:	06-30-2022
	Document Type:	Standard Operating Procedure
	Page Number:	1 of 4
	Department/Section:	Clinical Chemistry
	Document Title:	CREATININE ASSAY

PURPOSE:

To describe in detail how to prepare and process the Creatinine Assay test correctly and always in the same manner. Creatinine is used to evaluate kidney function. As the kidneys become impaired, creatinine levels will rise. Abnormally high levels of creatinine thus warn of possible malfunction or failure of the kidneys, sometimes even before patients manifest symptoms.

SCOPE:

Applies to all Clinical Chemistry Section Staff of Laboratory Department of Dr. Pablo O. Torre Memorial Hospital (DPOTMH)

PERSON RESPONSIBLE:

Doctors, Nurses, Medical Technologists, Pathologists, Patients, Clerks and Receptionist

GENERAL GUIDELINES:

- 1 No special preparation is necessary.
- 2 Collect specimen using standard laboratory procedures.
- 3 Refer to clinical chemistry section staff on duty on sample handling for recommended minimum sample volumes required by the analyzer.
- 4 Specimens collected shall be considered as biohazardous material.
- 5 The Medical Technologist shall handle specimens in stoppered containers to avoid contamination and evaporation.
- 6 If sample show Creatinine concentration that exceeds the system's reportable (dynamic) range, follow this procedure:
 - 6.1 Dilute 1-part the sample with 7% BSA.
 - 6.2 Reanalyze

 B.S. Aquino Drive, Bacolod City, Negros Occidental, 6100 DR. PABLO O. TORRE MEMORIAL HOSPITAL	Document Code:	DPOTMH-E-55-P01-S18
	Effective Date:	06-30-2022
	Document Type:	Standard Operating Procedure
	Page Number:	2 of 4
	Department/Section:	Clinical Chemistry
	Document Title:	CREATININE ASSAY

- 6.3 Multiply the results by 2 to obtain the original sample's creatinine concentration.
- 7 Avoid agitation or mixing of plasma samples after centrifugation. Resuspension of platelets into previously centrifuged plasma may lead to artificially elevated total bilirubin results.
 - 8 Remove serum from clots within 3 hours of collection.
 - 9 Remove serum from clots within four (4) days of collection since CK unstable in serum.
 - 10 Prior to blood collection, the Medical Technologist shall check on the wrist band for patient identification or for the policy on two (2) acceptable person identifiers applied such as allowing the patient to state his/her complete name, date of birth, address or the assigned identification number.
 - 11 Tubes must be labeled prior to blood extraction and a sufficient amount of blood shall be extracted to ensure that repeated additional examinations could be performed.
 - 12 Endorse the blood samples properly to the Medical Technologist on duty in Clinical Chemistry Section.

 DR. PABLO O. TORRE MEMORIAL HOSPITAL B.S. Aquino Drive, Bacolod City, Negros Occidental, 6100	Document Code:	DPOTMH-E-55-P01-S18
	Effective Date:	06-30-2022
	Document Type:	Standard Operating Procedure
	Page Number:	3 of 4
	Department/Section:	Clinical Chemistry
	Document Title:	CREATININE ASSAY

PROCEDURE:

1. Blood specimens collected in 5 mL red top tubes are checked if properly labeled and then subjected to centrifugation at 3500 rpm for 5 minutes.
2. Specimens are then bar-coded through the LIS and barcode labels are placed properly in the tubes without overlapping the handwritten details written by the phlebotomist.
3. Bar-coded specimens are placed in the analyzers sample racks. The Medical Technologist then press the start or on button of the analyzer to begin analyses.
4. Results are then copied from the LIS and verified by the medical technologist.
5. Once verified, results are released to the HIS wherein the nurses from the different nurse's station in the hospital as well as the releasing clerks can see and print the results.

REFERENCES:

1. Ortho Clinical Diagnostics Instruction for Use (IFU).

 DR. PABLO O. TORRE MEMORIAL HOSPITAL B.S. Aquino Drive, Bacolod City, Negros Occidental, 6100	Document Code:	DPOTMH-E-55-P01-S18
	Effective Date:	06-30-2022
	Document Type:	Standard Operating Procedure
	Page Number:	4 of 4
	Department/Section:	Clinical Chemistry
	Document Title:	CREATININE ASSAY

APPROVAL:

	Name/Title	Signature	Date
Prepared by:	ALEXIS F. CORDIA JR., RMT Section Head, Clinical Chemistry	<i>Alexis F. Cordia Jr.</i>	07/01/22
Verified:	MONICA B. VILLANUEVA, RMT, PhD Laboratory Manager	<i>M. Villanueva</i>	07-13-2022
	MELANIE ROSE B. ZERRUDO, MD, FPSP Chair, Department of Pathology	<i>M.R. Zerrudo</i>	07-13-2022
Reviewed:	DENNIS C. ESCALONA, MN, FPSQua Quality Assurance Supervisor	<i>D. Escalona</i>	07-13-2022
Recommending Approval:	ROSARIO D. ABARING, MAN, PhD Ancillary Division Officer	<i>R. Abaring</i>	07.13.2022
	FREDERIC IVAN L. TING, MD OIC - Total Quality Division	<i>F. Ting</i>	7/19/22
Approved:	GENESIS GOLDI D. GOLINGAN President and CEO	<i>G. Golingan</i>	9/7/22

 DR. PABLO O. TORRE MEMORIAL HOSPITAL B.S. Aquino Drive, Bacolod City, Negros Occidental, 6100	Document Code:	DPOTMH-E-55-P01-WI18
	Effective Date:	06-30-2022
	Document Type:	Work Instruction
	Page Number:	1 of 2
	Department/Section:	Clinical Chemistry
	Document Title:	CREATININE ASSAY

KEY TASKS	PERSON RESPONSIBLE
1. Collects blood specimen in 5 mL red top tubes, labels properly and then subjected to centrifugation at 3500 rpm for 5 minutes.	Medical Technologist
2. Bar codes specimens through the LIS and places properly in the tubes without overlapping the handwritten details written by the phlebotomist.	
3. Places bar-coded specimens in the analyzers sample racks.	
4. Presses the start or on button of the analyzer to begin analyses.	
5. Verifies results.	
6. Releases results after verification to the HIS wherein the nurses from the different nurse's station in the hospital as well as the Releasing Clerks can see and print the results.	

 DR. PABLO O. TORRE MEMORIAL HOSPITAL B.S. Aquino Drive, Bacolod City, Negros Occidental, 6100	Document Code:	DPOTMH-E-55-P01-WI18
	Effective Date:	06-30-2022
	Document Type:	Work Instruction
	Page Number:	2 of 2
	Department/Section:	Clinical Chemistry
	Document Title:	CREATININE ASSAY

APPROVAL:

	Name/Title	Signature	Date
Prepared by:	ALEXIS F. CORDIA JR., RMT Section Head, Clinical Chemistry	<i>Alexis F. Cordia Jr.</i>	07/01/2022
Verified:	MONICA B. VILLANUEVA, RMT, PhD Laboratory Manager	<i>Dr. Villanueva</i>	07-13-2022
	MELANIE ROSE B. ZERRUDO, MD, FPSP Chair, Department of Pathology	<i>MBZ</i>	07-13-2022
Reviewed:	DENNIS C. ESCALONA, MN, FPSQua Quality Assurance Supervisor	<i>D. Escalona</i>	07-13-2022
Recommending Approval:	ROSARIO D. ABARING, MAN, PhD Ancillary Division Officer	<i>R. Abaring</i>	07-13-2022
	FREDERIC IVAN L. TING, MD OIC - Total Quality Division	<i>F. Ting</i>	7/19/22
Approved:	GENESIS GOLDI D. GOLINGAN President and CEO	<i>G. Golingan</i>	9/2/22




DR. PABLO O. TORRE
MEMORIAL HOSPITAL

B.S. Aquino Drive,
Bacolod City,
Negros Occidental,
6100

Document Code:	DPOTMH-E-55-P01-FC18
Effective Date:	06-30-2022
Document Type:	Flowchart
Page Number:	1 of 2
Department/Section:	Clinical Chemistry
Document Title:	CREATININE ASSAY

FLOWCHART



 DR. PABLO O. TORRE MEMORIAL HOSPITAL B.S. Aquino Drive, Bacolod City, Negros Occidental, 6100	Document Code:	DPOTMH-E-55-P01-FC18
	Effective Date:	06-30-2022
	Document Type:	Flowchart
	Page Number:	2 of 2
	Department/Section:	Clinical Chemistry
	Document Title:	CREATININE ASSAY

APPROVAL:

	Name/Title	Signature	Date
Prepared by:	ALEXIS F. CORDIA JR., RMT Section Head, Clinical Chemistry	<i>Alexis F. Cordia Jr.</i>	07/01/2022
Verified:	MONICA B. VILLANUEVA, RMT, PhD Laboratory Manager	<i>Monica B. Villanueva</i>	07-13-2022
	MELANIE ROSE B. ZERRUDO, MD, FPSP Chair, Department of Pathology	<i>MRB</i>	07-13-2022
Reviewed:	DENNIS C. ESCALONA, MN, FPSQua Quality Assurance Supervisor	<i>Dennis C. Escalona</i>	07-13-2022
Recommending Approval:	ROSARIO D. ABARING, MAN, PhD Ancillary Division Officer	<i>Rosario D. Abaring</i>	07.13.2022
	FREDERIC IVAN L. TING, MD OIC - Total Quality Division	<i>Frederic Ivan L. Ting</i>	7/14/22
Approved:	GENESIS GOLDI D. GOLINGAN President and CEO	<i>Genesis Goldi D. Golangan</i>	9/7/22